Company Profile

Epizyme, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the treatment of people with cancer through the discovery, development, and commercialization of epigenetic medicines. The Company's lead product TAZVERIK (tazemetostat) is used for epithelioid sarcoma (ES), and follicular lymphoma (FL). Tazemetostat is an oral, selective small molecule inhibitor of the EZH2 histone methyltransferase (HMT), for the treatment of adult and pediatric patients aged 16 years and older with metastatic or locally advanced ES not eligible for complete resection. It is developing tazemetostat for lymphomas and B-cell malignancies, including B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), multiple myeloma and others. Its advanced product candidate, EZM0414, is an oral inhibitor of the SETD2 HMT. The Company is assessing the use of tazemetostat for immuno-oncology-sensitive tumors, such as small cell lung cancer, prostate cancer, and others.

Employees

250

Sector

Biotechnology & Medical Research

More about the company

06-21	Epizyme Withdraws Approval of New Drug Application for Tazverik (Tazemetostat) Tablet 200 Milligrams	CI
22-08-14	France's Ipsen Finalizes Purchase of US Biopharmaceutical Group Epizyme	MT
22-08-12	Epizyme Announces Management Changes	CI
22-08-12	Epizyme, Inc. Appoints Grant Bogle as Chief Executive Officer	CI
22-08-12	Epizyme, Inc.(NasdaqGS:EPZM) dropped from NASDAQ Composite Index	CI
22-08-12	Epizyme, Inc.(NasdaqGS:EPZM) dropped from S&P Global BMI Index	CI
22-08-12	Epizyme, Inc.(NasdaqGS:EPZM) dropped from S&P TMI Index	CI
22-08-11	Epizyme, Inc.(NasdaqGS:EPZM) dropped from NASDAQ Biotechnology Index	CI
22-08-10	Ipsen Biopharmaceuticals, Inc. completed the acquisition of Epizyme, Inc. from RP Management LLC and others.	CI
22-08-09	Earnings Flash (EPZM) EPIZYME Reports Q2 Revenue $27.5M	MT
22-08-09	Epizyme, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
22-08-05	France's Ipsen Extends Tender Offer To Purchase US Biopharmaceutical Epizyme	MT
22-08-01	Hutchmed Starts Bridging Study Follicular Lymphoma Treatment in China	MT

22-06-28	Cowen Downgrades Epizyme to Market Perform From Outperform; Price Target is $1.50	MT
22-06-27	Wedbush Cuts Epizyme to Neutral From Outperform, Price Target to $1.45 From $7, Citing Ipsen Offer	MT
22-06-03	HC Wainwright Adjusts Epizyme's Price Target to $6 From $8, Reiterates Buy Rating	MT
22-05-12	HC Wainwright Adjusts Epizyme Price Target to $8 From $10, Maintains Buy Rating	MT
22-05-10	Wedbush Adjusts Price Target for Epizyme to $7 From $9, Maintains Outperform Rating	MT

22-08-15	Ipsen completes acquisition of Epizyme expanding its portfolio in oncology	AQ
22-08-12	EPIZYME, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
22-08-09	Epizyme : Reports Second Quarter 2022 Financial Results and Provides Business Update - Form 8-K	PU
22-08-09	EPIZYME, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
22-08-09	Epizyme: Q2 Earnings Snapshot	AQ

22-08-12	Ipsen a finalisé le rachat de la société américaine Epizyme spécialisée en oncologie
22-08-05	Bolsa de Madrid: ¿Agosto siguiendo los pasos de julio?
22-08-05	EN DIRECT DES MARCHES : Stellantis, Sanofi, Ipsen, EDF, Allianz, Lyft, Ahold Delhaize, Crédit Suisse...
22-08-05	Ipsen : OPA sur Epizyme prolongée jusqu'au 11 août
22-08-05	Août sur la lancée de Juillet ?

Manager	Title	Age	Since
Christelle Huguet PSD	President	59	2022-08-11
Jennifer Benenson SEC	Corporate Secretary	-	-
Abla Abrial TRE	Treasurer	-	-

Epizyme, Inc. Stock

Stocks

EPZM

US29428V1044

Biotechnology & Medical Research

Latest news : Epizyme, Inc.

Analysts' recommendations: Epizyme, Inc.

Press Releases: Epizyme, Inc.

News in other languages: Epizyme, Inc.

Quotes and Performance

Managers and Directors: Epizyme, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Director	Title	Age	Since
François-Maurice Garnier BRD	Director/Board Member	64	2022-08-11
Aymeric Le Chatelier BRD	Director/Board Member	57	2022-08-11
Alan Sokaler BRD	Director/Board Member	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
8/12/22	Roy Beveridge	Issuer sale	Director	46,037	0.0273%
8/12/22	Pablo Legorreta	Tender	Director	31,950,388	18.9809%
8/12/22	Victoria Richon	Issuer sale	Director	22,608	0.0134%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EPIZYME, INC.	-1.34%	-0.68%	-	-	247M
WUXI APPTEC CO., LTD.	-4.31%	-6.62%	+65.79%	+98.02%	72.12B
ARGENX SE	-4.19%	+1.05%	+52.79%	+85.53%	65.85B
BIONTECH SE	-3.22%	+23.17%	+1.75%	-5.23%	29.28B
INSMED INCORPORATED	-1.42%	-3.38%	-5.99%	+465.34%	27.47B
WUXI BIOLOGICS (CAYMAN) INC.	+4.22%	+4.26%	+52.19%	+14.21%	26.7B
GENMAB A/S	-1.81%	+0.38%	+34.52%	-18.33%	20.06B
PHARMAESSENTIA CORPORATION	+5.36%	+4.61%	+270.18%	+415.10%	18.22B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.57%	-3.78%	+11.11%	+517.39%	16.4B
EXELIXIS, INC.	+0.87%	+4.26%	+41.21%	+150.80%	13.4B
Average	-0.60%	+5.35%	+58.17%	+191.42%	32.17B
Weighted average by Cap.	-1.86%	+3.13%	+54.75%	+149.95%